A randomized controlled phase II trial of riluzole in early multiple sclerosis

Emmanuelle Waubant, Amir Hadi Maghzi, Nisha Revirajan, Rebecca Spain, Laura Julian, Ellen Mahar Mowry, Jacqueline Marcus, Shuang Liu, Chengshi Jin, Ari Green, Charles E. McCulloch, Daniel Pelletier

Research output: Contribution to journalArticle

Abstract

Objectives: We evaluated the effect of riluzole versus placebo added to weekly IM interferon beta-1a in early multiple sclerosis (MS). Methods: This is a randomized (1:1), double-blind, placebo-controlled trial of riluzole 50 mg twice daily in subjects with MS onset less than 1 year prior. Trial participation was up to 3 years. The primary endpoint was change in percent brain volume change. Secondary endpoints included changes in normalized gray and normal-appearing white matter volumes, retinal nerve fiber layer thickness (RNFL), MS Functional Composite and Symbol Digit Modalities Test scores. Mixed model regression analysis was used to compare the changes over time between groups. Results: Forty-three subjects were randomized to study drug (22 riluzole, 21 placebo). Baseline characteristics were overall similar between groups except for older age (P = 0.042), higher normalized cerebrospinal fluid volume (P = 0.050), lower normalized gray matter volume (P = 0.14), and thinner RNFL (P = 0.043) in the riluzole group. In the primary analysis, percent brain volume change in the placebo group decreased at a rate of 0.49% per year whereas the riluzole group decreased by 0.86% per year (0.37% more per year; 95% CI −0.78, 0.024; P = 0.065). Although age did not influence the rate of brain volume decline, the difference between groups was attenuated after adjustment for baseline normalized gray matter and lesion volume (0.26% more per year in riluzole group; 95% CI −0.057, 0.014; P = 0.22). Analyses of secondary outcomes showed no differences between groups. Interpretation: This trial provides class 1 evidence that riluzole treatment does not meaningfully reduce brain atrophy progression in early MS.

Original languageEnglish (US)
Pages (from-to)340-347
Number of pages8
JournalAnnals of Clinical and Translational Neurology
Volume1
Issue number5
DOIs
StatePublished - May 1 2014
Externally publishedYes

Fingerprint

Riluzole
Multiple Sclerosis
Placebos
Brain
Nerve Fibers
Atrophy
Cerebrospinal Fluid
Regression Analysis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

A randomized controlled phase II trial of riluzole in early multiple sclerosis. / Waubant, Emmanuelle; Maghzi, Amir Hadi; Revirajan, Nisha; Spain, Rebecca; Julian, Laura; Mowry, Ellen Mahar; Marcus, Jacqueline; Liu, Shuang; Jin, Chengshi; Green, Ari; McCulloch, Charles E.; Pelletier, Daniel.

In: Annals of Clinical and Translational Neurology, Vol. 1, No. 5, 01.05.2014, p. 340-347.

Research output: Contribution to journalArticle

Waubant, E, Maghzi, AH, Revirajan, N, Spain, R, Julian, L, Mowry, EM, Marcus, J, Liu, S, Jin, C, Green, A, McCulloch, CE & Pelletier, D 2014, 'A randomized controlled phase II trial of riluzole in early multiple sclerosis', Annals of Clinical and Translational Neurology, vol. 1, no. 5, pp. 340-347. https://doi.org/10.1002/acn3.60
Waubant, Emmanuelle ; Maghzi, Amir Hadi ; Revirajan, Nisha ; Spain, Rebecca ; Julian, Laura ; Mowry, Ellen Mahar ; Marcus, Jacqueline ; Liu, Shuang ; Jin, Chengshi ; Green, Ari ; McCulloch, Charles E. ; Pelletier, Daniel. / A randomized controlled phase II trial of riluzole in early multiple sclerosis. In: Annals of Clinical and Translational Neurology. 2014 ; Vol. 1, No. 5. pp. 340-347.
@article{3978578531d24f20a972c58cad872fe9,
title = "A randomized controlled phase II trial of riluzole in early multiple sclerosis",
abstract = "Objectives: We evaluated the effect of riluzole versus placebo added to weekly IM interferon beta-1a in early multiple sclerosis (MS). Methods: This is a randomized (1:1), double-blind, placebo-controlled trial of riluzole 50 mg twice daily in subjects with MS onset less than 1 year prior. Trial participation was up to 3 years. The primary endpoint was change in percent brain volume change. Secondary endpoints included changes in normalized gray and normal-appearing white matter volumes, retinal nerve fiber layer thickness (RNFL), MS Functional Composite and Symbol Digit Modalities Test scores. Mixed model regression analysis was used to compare the changes over time between groups. Results: Forty-three subjects were randomized to study drug (22 riluzole, 21 placebo). Baseline characteristics were overall similar between groups except for older age (P = 0.042), higher normalized cerebrospinal fluid volume (P = 0.050), lower normalized gray matter volume (P = 0.14), and thinner RNFL (P = 0.043) in the riluzole group. In the primary analysis, percent brain volume change in the placebo group decreased at a rate of 0.49{\%} per year whereas the riluzole group decreased by 0.86{\%} per year (0.37{\%} more per year; 95{\%} CI −0.78, 0.024; P = 0.065). Although age did not influence the rate of brain volume decline, the difference between groups was attenuated after adjustment for baseline normalized gray matter and lesion volume (0.26{\%} more per year in riluzole group; 95{\%} CI −0.057, 0.014; P = 0.22). Analyses of secondary outcomes showed no differences between groups. Interpretation: This trial provides class 1 evidence that riluzole treatment does not meaningfully reduce brain atrophy progression in early MS.",
author = "Emmanuelle Waubant and Maghzi, {Amir Hadi} and Nisha Revirajan and Rebecca Spain and Laura Julian and Mowry, {Ellen Mahar} and Jacqueline Marcus and Shuang Liu and Chengshi Jin and Ari Green and McCulloch, {Charles E.} and Daniel Pelletier",
year = "2014",
month = "5",
day = "1",
doi = "10.1002/acn3.60",
language = "English (US)",
volume = "1",
pages = "340--347",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - A randomized controlled phase II trial of riluzole in early multiple sclerosis

AU - Waubant, Emmanuelle

AU - Maghzi, Amir Hadi

AU - Revirajan, Nisha

AU - Spain, Rebecca

AU - Julian, Laura

AU - Mowry, Ellen Mahar

AU - Marcus, Jacqueline

AU - Liu, Shuang

AU - Jin, Chengshi

AU - Green, Ari

AU - McCulloch, Charles E.

AU - Pelletier, Daniel

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Objectives: We evaluated the effect of riluzole versus placebo added to weekly IM interferon beta-1a in early multiple sclerosis (MS). Methods: This is a randomized (1:1), double-blind, placebo-controlled trial of riluzole 50 mg twice daily in subjects with MS onset less than 1 year prior. Trial participation was up to 3 years. The primary endpoint was change in percent brain volume change. Secondary endpoints included changes in normalized gray and normal-appearing white matter volumes, retinal nerve fiber layer thickness (RNFL), MS Functional Composite and Symbol Digit Modalities Test scores. Mixed model regression analysis was used to compare the changes over time between groups. Results: Forty-three subjects were randomized to study drug (22 riluzole, 21 placebo). Baseline characteristics were overall similar between groups except for older age (P = 0.042), higher normalized cerebrospinal fluid volume (P = 0.050), lower normalized gray matter volume (P = 0.14), and thinner RNFL (P = 0.043) in the riluzole group. In the primary analysis, percent brain volume change in the placebo group decreased at a rate of 0.49% per year whereas the riluzole group decreased by 0.86% per year (0.37% more per year; 95% CI −0.78, 0.024; P = 0.065). Although age did not influence the rate of brain volume decline, the difference between groups was attenuated after adjustment for baseline normalized gray matter and lesion volume (0.26% more per year in riluzole group; 95% CI −0.057, 0.014; P = 0.22). Analyses of secondary outcomes showed no differences between groups. Interpretation: This trial provides class 1 evidence that riluzole treatment does not meaningfully reduce brain atrophy progression in early MS.

AB - Objectives: We evaluated the effect of riluzole versus placebo added to weekly IM interferon beta-1a in early multiple sclerosis (MS). Methods: This is a randomized (1:1), double-blind, placebo-controlled trial of riluzole 50 mg twice daily in subjects with MS onset less than 1 year prior. Trial participation was up to 3 years. The primary endpoint was change in percent brain volume change. Secondary endpoints included changes in normalized gray and normal-appearing white matter volumes, retinal nerve fiber layer thickness (RNFL), MS Functional Composite and Symbol Digit Modalities Test scores. Mixed model regression analysis was used to compare the changes over time between groups. Results: Forty-three subjects were randomized to study drug (22 riluzole, 21 placebo). Baseline characteristics were overall similar between groups except for older age (P = 0.042), higher normalized cerebrospinal fluid volume (P = 0.050), lower normalized gray matter volume (P = 0.14), and thinner RNFL (P = 0.043) in the riluzole group. In the primary analysis, percent brain volume change in the placebo group decreased at a rate of 0.49% per year whereas the riluzole group decreased by 0.86% per year (0.37% more per year; 95% CI −0.78, 0.024; P = 0.065). Although age did not influence the rate of brain volume decline, the difference between groups was attenuated after adjustment for baseline normalized gray matter and lesion volume (0.26% more per year in riluzole group; 95% CI −0.057, 0.014; P = 0.22). Analyses of secondary outcomes showed no differences between groups. Interpretation: This trial provides class 1 evidence that riluzole treatment does not meaningfully reduce brain atrophy progression in early MS.

UR - http://www.scopus.com/inward/record.url?scp=84930756359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930756359&partnerID=8YFLogxK

U2 - 10.1002/acn3.60

DO - 10.1002/acn3.60

M3 - Article

VL - 1

SP - 340

EP - 347

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

SN - 2328-9503

IS - 5

ER -